Coming off an incretin · defend the band, not the number
INGESTIBLE // MOLECULAR
◇ WHAT IT IS
Most people who start a GLP-1 or GLP-1/GIP drug eventually stop — because of cost, supply, side effects, or because they reached what they came for. Almost nothing written about these drugs prepares them for what happens next. This protocol is about that part, and it starts with a number you should see before anything else: in the trial built to answer this question, only 16.6% of people who stopped held even 80% of what they had lost. Five out of six did not. That is the base rate, and it is not a story about willpower.
Here is the part that makes this worth doing anyway. The damage is not all-or-nothing. When researchers sorted people by how much they regained, the metabolic reversal tracked the tier almost step for step — and the group that held regain under about a quarter of what they had lost finished the year with waist, cholesterol and fasting insulin essentially unchanged from their best. You are not trying to keep every kilogram. You are trying to stay in a band.
One honest caveat up front, because it shapes everything below. The largest pooled analysis of discontinuation reports that regain happens 'regardless of lifestyle interventions'. This protocol does not claim to override that, and you should distrust anyone who claims otherwise. What it does is build the substrate that plausibly decides which tier you land in, and set up the measurements that tell you where you actually are — early enough to act.
◇ THE COMPONENTS
The resistance substrateBuilt BEFORE the taper, not after. The only arm in the body-composition literature that meaningfully improves the lean-mass fraction (17.5% vs ~26%).
Protein floorThe nutritional half of the same lever. Held through the taper, when appetite returns and dietary structure is most likely to collapse.
The four numbersWaist, fasting insulin, non-HDL cholesterol, HbA1c — the parameters shown to move on withdrawal, and to move quietly.
A physician who planned it with youNon-negotiable. Tapering, pausing or stopping a prescription incretin is a clinical decision, and a planned exit is a different event from a lapsed prescription.
◇ HOW TO DEPLOY — DAILY TIMING
BEFORE YOU TAPEREstablish resistance training 2–3×/week and hold it for at least 10 weeks while still on the drug — the substrate has to exist before the drug leavesTraining
BEFORE YOU TAPERRecord your reference set: weight, waist, fasting insulin, non-HDL-C, HbA1c. This is the line you are defending, and you cannot defend a line you never drewBaseline
WITH YOUR PHYSICIANAgree the exit as a plan with a shape — the taper, the check-in dates, and the threshold at which you would reconsiderClinical
DAILY, THROUGH THE TAPERHold the protein floor and the training schedule. Appetite returns before structure does; the structure is the thing that has to be already standingSubstrate
WEEKS 4, 12, 26, 52Re-measure the same four numbers. Compute regain as a share of what you lost — the tier is the metric, not the scale weightMeasurement
IF YOU CROSS 25%Treat it as data, not failure, and take it back to your physician. The tiers above 25% are where the metabolic reversal accelerates — that is the moment the conversation is worth having againClinical
◇ WHAT CHANGES IN YOUR DAY
You stop treating the exit as an event that happens to you and start treating it as a phase with a shape — which is the difference between discovering the regain at month nine and seeing it at week four.
You get a target that is defensible rather than heroic. Holding a band is a goal you can actually hit; holding every kilogram is a goal that five out of six people miss.
You keep the part you were actually buying. The waist, the insulin, the blood pressure — not the number on the scale — are what the improvement was made of, and the tier data says those can survive a partial regain.
2035 HORIZONPROJECTION · NOT PROVEN FACT
Trials that test the exit instead of assuming it
Every discontinuation finding we have is an observation of what happened to people who stopped — nobody has randomized anyone to a structured maintenance protocol at withdrawal. That trial is the obvious next one, and until it is run, the defence in this protocol remains inference from adjacent evidence rather than proof. If it reads out well, this page gets rewritten with a much stronger claim. If it reads out badly, it gets rewritten with a much weaker one. Projection, not fact.
Maintenance dosing as a middle path
The framing of on-versus-off may turn out to be a false binary. Lower-dose maintenance regimens are being explored as a way to hold the result without the full cost and side-effect load — but the evidence is not yet there, and this is a physician's decision in any case, not a self-directed experiment. Watch this space rather than acting on it.
⧗ OPERATOR ADVISORY
Informational, not medical advice. Tirzepatide and semaglutide are prescription pharmaceuticals: starting, tapering, pausing and stopping are clinical decisions made with a licensed physician who knows your history — never self-directed. This protocol contains no dosing guidance and is not a schedule for coming off a medicine. It is written to make you a better-informed participant in a conversation with your doctor, and to name the measurements worth taking. If you are currently on an incretin and considering stopping, that conversation is the first step, not this page.
◇ THE STANDARD // APPLIED TO THIS ASSET
◇ THE AUDIT — THIS ASSET, ON THE STANDARDCALIBRATED CERTAINTY = ∛(E · C · I)
Applies to healthy apex, not only to clinical deficit.
03 IMPLEMENTATIONLIMITING LAYER48
Survives a demanding calendar. Zero executive friction.
CONDITIONAL
Deployable with named caveats. Context-dependent.
The sliders start at the OCCABUZZ assessment for this asset. Drag any layer to test the standard against our call.
The score is a geometric mean — a single failed layer collapses it. Excellence in two cannot rescue a gap in the third. That is why hype scores low and proven, feasible, broadly-applicable work scores high. The restraint is the product.